NsGene A/S Patent applications |
Patent application number | Title | Published |
20150231208 | Treatment of Allodynia, Hyperalgsia, Spontaneous Pain, and Phantom Pain - The present invention relates to use of Cometin in a method of treatment of allodynia, hyperalgesia, spontaneous pain and/or phantom pain. In a preferred embodiment the disorder to be treated is thermal allodynia and thermal hyperalgesia. The Cometin polypeptide may be delivered as a polypeptide or by administration of an expression vector for expression of Cometin, a cell line transformed or transduced with said vector and a capsule comprising said cells. | 08-20-2015 |
20140377341 | CELL LINES AND THEIR USE IN ENCAPSULATED CELL BIODELIVERY - The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide. | 12-25-2014 |
20130267464 | THERAPEUTIC USE OF A GROWTH FACTOR, METRNL - The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects. | 10-10-2013 |
20130261543 | IMPLANTABLE CELL DEVICE WITH SUPPORTIVE AND RADIAL DIFFUSIVE SCAFFOLDING - According to an embodiment of the invention, an implantable cell device is disclosed. The device includes a membrane defining and enclosing a chamber; a distance means, within the chamber, for reducing diffusion distance for a biologically active factor to across the membrane; and a support means, within the chamber, for increasing cell support surface area per unit volume of the chamber for distributing cells. | 10-03-2013 |
20120252726 | NOVEL NEUROTROPHIC FACTORS - The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same. | 10-04-2012 |
20120184492 | THERAPEUTIC USE OF A GROWTH FACTOR, NSG33 - The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein, NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences. | 07-19-2012 |
20120108518 | TREATMENT OF ALLODYNIA, HYPERALGESIA, SPONTANEOUS PAIN AND PHANTOM PAIN - The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia. | 05-03-2012 |
20120021039 | EXPRESSION OF NEUROPEPTIDES IN MAMMALIAN CELLS - The present application relates to expression constructs capable of securing correct processing of neuropeptides upon expression in mammalian cells, and to mammalian cells secreting correctly processed peptides. One exemplary peptide is galanin. The application also relates to devices containing neuropeptide secreting cells, which devices may be used for the treatment of epilepsy and other disorders of the nervous system. All references cited herein are incorporated by reference. | 01-26-2012 |
20110003358 | CULTURES OF GFAP+ NESTIN+ CELLS THAT DIFFERENTIATE TO NEURONS - Cultures of cells immunoreactive for glial fibrillary acidic protein (GFAP), as well as for the intermediate filament marker nestin were grown in a medium including epidermal growth factor (EGF) and serum. The cultured cells had the morphology of astroglial cells. The cells can be proliferated in adherent or suspension cultures. Depending on the culture conditions, the cells can be induced to differentiate to neurons or glial cells. The cultures can be expanded over a large number of passages during several months, and survive, express an astroglial phenotype and integrate well after transplantation into both neonatal and adult rat forebrain. | 01-06-2011 |
20100292142 | NOVEL NEUROTROPHIC FACTORS - The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same. | 11-18-2010 |
20100234293 | Novel Neurotrophic Factors - The invention relates to neublastinneurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same. | 09-16-2010 |
20080318853 | Diagnostic and Therapeutic Use of a Novel Growth Factor, Neublasmin - The present invention relates to the field of diagnostic and therapeutic use of proteins and genes, in particular to the diagnostic and therapeutic use of a secreted human hormone/growth factor, Neublasmin, and use or the gene coding for Neublasmin in the diagnosis and treatment of testicular disorders, in particular diagnosis and treatment of germ cell tumours and infertility. The invention also relates to use of Neublasmin in the treatment of CNS disorders. Neublasmin is expressed at high levels in human adult testicles and in developing mouse testicles from pn 22 and onwards. Expression or Neublasmin is strongly up-regulated in carcinoma in situ. Expression is also seen in foetal and adult brain. | 12-25-2008 |
20080286323 | Human Therapeutic Cells Secreting Nerve Growth Factor - The present invention relates to human cell lines genetically modified to overexpress bioactive NGF. In another aspect the present invention relates to encapsulated human cell lines genetically modified to overexpress bioactive NGF, which can be used in therapy of Alzheimer's disease, peripheral neuropathy and other neurological disorders amenable to local and prolonged NGF therapy. | 11-20-2008 |
20080233647 | NOVEL NEUROTROPHIC FACTORS - The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same. | 09-25-2008 |